Dual amylin and calcitonin receptor agonists (DACRAs) are a class of drugs that act as agonists at the amylin receptor and calcitonin receptor that are under development as therapies for obesity and type 2 diabetes. Examples are cagrilintide, Petrelintide, ACCG-2671 and the KBP family derived from salmon calcitonin, [1] including KBP‐042, [2] KBP-066A, [3] KBP-089, [4] and KBP-336. [5]